A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Pamela Munster
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Pamela Munster
Professor, Medicine, School of Medicine. Authored (or co-authored) 143 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Genentech, Inc.
- ID
- NCT04449874
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 498 study participants
- Last Updated